Open access
Sep 2026
Cannabinol β‑O-Glucoside Inhibitors of the Keap1-Nrf2 Interaction: A Novel Therapeutic Strategy for Parkinson's Disease.
Computer analyses supported its Keap1-targeting activity, identifying CS-11 as a promising Parkinson’s disease therapeutic candidate and showing the strongest neuroprotective effect in a Parkinson’s disease model.
P. Deshmukh, Snehal U. Aouti, Ashok Sridhar et al.
· ACS Medicinal Chemistry Lett... · 0 citations